NCT07077369 2025-07-22
WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy
West China Hospital
Phase 1 Not yet recruiting
West China Hospital
Tianjin Medical University Cancer Institute and Hospital
The First Affiliated Hospital of Bengbu Medical University
Fujian Cancer Hospital